{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:17:29Z","timestamp":1771229849609,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103690","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:42:39Z","timestamp":1771227759000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparing the Efficacy of Desidustat Versus Erythropoietin in the Management of Anemia in Patients With Dialysis-Na\u00efve Chronic Kidney Disease: A Randomized Open-Label Trial"],"prefix":"10.7759","author":[{"given":"Hiramani","family":"Rabha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Quaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Shariq","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32977-0","article-title":"The global burden of chronic kidney disease","volume":"395","author":"Cockwell P","year":"2020","unstructured":"Cockwell P, Fisher LA. The global burden of chronic kidney disease. Lancet. 2020, 395:662-4. 10.1016\/S0140-6736(19)32977-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"Kovesdy CP","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022, 12:7-11. 10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl (2011)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30440-1","article-title":"Anaemia among men in India: a nationally representative cross-sectional study","volume":"7","author":"Didzun O","year":"2019","unstructured":"Didzun O, De Neve JW, Awasthi A, et al.. Anaemia among men in India: a nationally representative cross-sectional study. Lancet Glob Health. 2019, 7:e1685-94. 10.1016\/S2214-109X(19)30440-1","journal-title":"Lancet Glob Health"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01498-0","article-title":"Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018","volume":"27","author":"Kinyoki D","year":"2021","unstructured":"Kinyoki D, Osgood-Zimmerman AE, Bhattacharjee NV, Kassebaum NJ, Hay SI. Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nat Med. 2021, 27:1761-82. 10.1038\/s41591-021-01498-0","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.07.011","article-title":"Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases","volume":"25","author":"Poggiali E","year":"2014","unstructured":"Poggiali E, Migone De Amicis M, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med. 2014, 25:12-7. 10.1016\/j.ejim.2013.07.011","journal-title":"Eur J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2008.08.006","article-title":"Iron metabolism in the anemia of chronic disease","volume":"1790","author":"Weiss G","year":"2009","unstructured":"Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta. 2009, 1790:682-93. 10.1016\/j.bbagen.2008.08.006","journal-title":"Biochim Biophys Acta"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: global dimension and perspectives","volume":"382","author":"Jha V","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al.. Chronic kidney disease: global dimension and perspectives. Lancet. 2013, 382:260-72. 10.1016\/S0140-6736(13)60687-X","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01744-w","article-title":"Desidustat: first approval","volume":"82","author":"Dhillon S","year":"2022","unstructured":"Dhillon S. Desidustat: first approval. Drugs. 2022, 82:1207-12. 10.1007\/s40265-022-01744-w","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt WM","year":"2010","unstructured":"Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, G\u00fcnzler V, Eckardt KU. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol. 2010, 21:2151-6. 10.1681\/ASN.2010010116","journal-title":"J Am Soc Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2022.100102","article-title":"Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state","volume":"3","author":"Joharapurkar AA","year":"2022","unstructured":"Joharapurkar AA, Patel VJ, Kshirsagar SG, et al.. Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. Curr Res Pharmacol Drug Discov. 2022, 3:100102. 10.1016\/j.crphar.2022.100102","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.09.010","article-title":"The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?","volume":"52","author":"Singh AK","year":"2008","unstructured":"Singh AK. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?. Am J Kidney Dis. 2008, 52:S5-13. 10.1053\/j.ajkd.2008.09.010","journal-title":"Am J Kidney Dis"},{"key":"ref12","article-title":"Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects","volume":"15","author":"Provatopoulou ST","year":"2011","unstructured":"Provatopoulou ST, Ziroyiannis PN. Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects. Hippokratia. 2011, 15:109-15.","journal-title":"Hippokratia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000523949","article-title":"Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang S","year":"2022","unstructured":"Gang S, Khetan P, Varade D, et al.. Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D). Am J Nephrol. 2022, 53:343-51. 10.1159\/000523949","journal-title":"Am J Nephrol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.03.023","article-title":"Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"44","author":"Pisoni RL","year":"2004","unstructured":"Pisoni RL, Bragg-Gresham JL, Young EW, et al.. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004, 44:94-111. 10.1053\/j.ajkd.2004.03.023","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref16","article-title":"Preventability and severity assessment in reporting adverse drug reactions","volume":"49","author":"Hartwig SC","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992, 49:2229-32.","journal-title":"Am J Hosp Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000523961","article-title":"Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND)","volume":"53","author":"Agrawal D","year":"2022","unstructured":"Agrawal D, Varade D, Shah H, et al.. Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am J Nephrol. 2022, 53:352-60. 10.1159\/000523961","journal-title":"Am J Nephrol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00215-8","article-title":"Symptoms and impacts in anemia of chronic kidney disease","volume":"4","author":"Mathias SD","year":"2020","unstructured":"Mathias SD, Blum SI, Sikirica V, Johansen KL, Colwell HH, Okoro T. Symptoms and impacts in anemia of chronic kidney disease. J Patient Rep Outcomes. 2020, 4:64. 10.1186\/s41687-020-00215-8","journal-title":"J Patient Rep Outcomes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae069.1488","article-title":"Retrospective analysis of the real-world experience of desidustat in the treatment of chronic kidney disease induced anemia","volume":"39","author":"Pahari D","year":"2024","unstructured":"Pahari D. Retrospective analysis of the real-world experience of desidustat in the treatment of chronic kidney disease induced anemia. Nephrol Dial Transplant. 2024, 39:gfae069-1488-708. 10.1093\/ndt\/gfae069.1488","journal-title":"Nephrol Dial Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD","volume":"32","author":"Nangaku M","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, et al.. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. 2021, 32:1779-90. 10.1681\/ASN.2020091311","journal-title":"J Am Soc Nephrol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar DV","year":"2019","unstructured":"Parmar DV, Kansagra KA, Patel JC, et al.. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019, 49:470-8. 10.1159\/000500232","journal-title":"Am J Nephrol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne DW","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, et al.. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021, 6:624-35. 10.1016\/j.ekir.2020.11.034","journal-title":"Kidney Int Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000518072","article-title":"Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study","volume":"52","author":"Yamamoto H","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T. Molidustat for renal anemia in nondialysis patients previously treated with erythropoiesis-stimulating agents: a randomized, open-label, phase 3 study. Am J Nephrol. 2021, 52:884-93. 10.1159\/000518072","journal-title":"Am J Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-016-1278-z","article-title":"GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients","volume":"48","author":"Lukaszyk E","year":"2016","unstructured":"Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Bodzenta-Lukaszyk A, Malyszko J. GDF-15, iron, and inflammation in early chronic kidney disease among elderly patients. Int Urol Nephrol. 2016, 48:839-44. 10.1007\/s11255-016-1278-z","journal-title":"Int Urol Nephrol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2023.02.003","article-title":"Growth differentiation factor 15 (GDF-15) in kidney diseases","volume":"114","author":"Delrue C","year":"2023","unstructured":"Delrue C, Speeckaert R, Delanghe JR, Speeckaert MM. Growth differentiation factor 15 (GDF-15) in kidney diseases. Adv Clin Chem. 2023, 114:1-46. 10.1016\/bs.acc.2023.02.003","journal-title":"Adv Clin Chem"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01505-9","article-title":"GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease","volume":"49","author":"Farag NM","year":"2023","unstructured":"Farag NM, Mousa M, Elsayed E, Ismeil A. GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease. Ital J Pediatr. 2023, 49:106. 10.1186\/s13052-023-01505-9","journal-title":"Ital J Pediatr"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30331-6","article-title":"Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis","volume":"13","author":"Yoshida S","year":"2023","unstructured":"Yoshida S, Saito T, Shibagaki K, Hirao K, Yuza T, Tomosugi N, Honda H. Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis. Sci Rep. 2023, 13:3181. 10.1038\/s41598-023-30331-6","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.149387","article-title":"Investigating the therapeutic effects and mechanisms of roxadustat on peritoneal fibrosis based on the TGF-\u03b2\/Smad pathway","volume":"693","author":"Wang L","year":"2024","unstructured":"Wang L, Fan J, Yang T, Shen J, Wang L, Ge W. Investigating the therapeutic effects and mechanisms of roxadustat on peritoneal fibrosis based on the TGF-\u03b2\/Smad pathway. Biochem Biophys Res Commun. 2024, 693:149387. 10.1016\/j.bbrc.2023.149387","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428822-comparing-the-efficacy-of-desidustat-versus-erythropoietin-in-the-management-of-anemia-in-patients-with-dialysis-nave-chronic-kidney-disease-a-randomized-open-label-trial","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:42:40Z","timestamp":1771227760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428822-comparing-the-efficacy-of-desidustat-versus-erythropoietin-in-the-management-of-anemia-in-patients-with-dialysis-nave-chronic-kidney-disease-a-randomized-open-label-trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.103690","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}